Effect of non‐recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta‐analysis
X Liu, M Huang, C Ye, X Xiao, C Yan - Clinical Cardiology, 2021 - Wiley Online Library
Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …
[HTML][HTML] Association between genetic polymorphisms and bleeding in patients on direct oral anticoagulants
Objectives: The purpose of our study is to investigate the effects of apolipoprotein B (APOB)
and APOE gene polymorphisms on bleeding complications in patients receiving direct oral …
and APOE gene polymorphisms on bleeding complications in patients receiving direct oral …
Effects of direct oral anticoagulants' nonrecommended dose in atrial fibrillation: a meta-analysis
Background: The efficacy and safety profiles of nonrecommended direct oral anticoagulant
(DOAC) doses in patients with nonvalvular atrial fibrillation (NVAF) are still undefined …
(DOAC) doses in patients with nonvalvular atrial fibrillation (NVAF) are still undefined …
[PDF][PDF] Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation
TS Shahzada, CL Guo, APW Lee - Hong Kong Medical Journal, 2022 - hkmj.org
Introduction: Patients with non-valvular atrial fibrillation (NVAF) may be prescribed warfarin
or a non–vitamin K oral anticoagulant (NOAC). There is increasing evidence that NOACs are …
or a non–vitamin K oral anticoagulant (NOAC). There is increasing evidence that NOACs are …
[HTML][HTML] Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
AB Diaz, J Chow, FK Hoo, KW Koh, GCK Lee… - Drugs in …, 2023 - ncbi.nlm.nih.gov
Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or
systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous …
systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous …
[HTML][HTML] Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: a PRISMA-compliant article
SM Kim, ET Jeon, JM Jung, JS Lee - Medicine, 2021 - journals.lww.com
Background and Purpose: This study aimed to evaluate the comparative efficacy and safety
of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non …
of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non …
[PDF][PDF] Efficacy and Safety of Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
PB Roy, VN Tejani, SS Dhillon, N Damarlapally… - Cureus, 2023 - cureus.com
In recent times, novel oral anticoagulants (NOACs)/direct oral anticoagulants (DOACs) have
emerged as an alternative to the traditionally used Vitamin K oral antagonists (VKA) like …
emerged as an alternative to the traditionally used Vitamin K oral antagonists (VKA) like …
Net clinical benefit of a reduced dose of DOACs in non-valvular atrial fibrillation: A meta-analysis of randomized trials
C Thomopoulos, J Ntalakouras, D Polyzos… - Pharmacological …, 2022 - Elsevier
Background In standard dosing, direct Oral Anticoagulants (DOACs) are used as an
alternative to warfarin to prevent ischemic stroke and systemic embolism in non-valvular …
alternative to warfarin to prevent ischemic stroke and systemic embolism in non-valvular …
[HTML][HTML] Meta-análisis: Eficacia y seguridad de apixabán frente a warfarina en pacientes con fibrilación auricular para profilaxis de eventos cardiovasculares adversos
MAI Vallejo, P Blandin-Lituma - CEDAMAZ, 2022 - revistas.unl.edu.ec
Los pacientes con fibrilación auricular (FA) requieren terapia anticoagulante para prevenir
eventos cardiovasculares adversos. Un fármaco muy empleado es warfarina con beneficios …
eventos cardiovasculares adversos. Un fármaco muy empleado es warfarina con beneficios …
Nuevos anticoagulantes orales
IÍ Vázquez, MM Fernández, EMR Lema… - Procesos clínicos …, 2022 - books.google.com
La introducción de los antagonistas de la vitamina K (AVK), hace más de 60 años, fue un
gran avance que transformó el tratamiento de la fibrilación auricular y el tromboembolismo …
gran avance que transformó el tratamiento de la fibrilación auricular y el tromboembolismo …